Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Two analgesic drugs may one day be repurposed as anti-tumor therapies

Two analgesic drugs may one day be repurposed as anti-tumor therapies

New research aims to develop targeted therapy for hard-to-treat osteosarcoma

New research aims to develop targeted therapy for hard-to-treat osteosarcoma

Cleveland Clinic team uncovers genetic link to osteosarcoma

Cleveland Clinic team uncovers genetic link to osteosarcoma

UPR modulators show promise in treating cancer-related bone disease

UPR modulators show promise in treating cancer-related bone disease

Strategic tips for early-stage animal health companies facing regulatory challenges

Strategic tips for early-stage animal health companies facing regulatory challenges

New mouse model reveals key role of osteocytes in osteogenesis imperfecta

New mouse model reveals key role of osteocytes in osteogenesis imperfecta

New small molecule shows promise against cutaneous HPV infections

New small molecule shows promise against cutaneous HPV infections

Targeting the tumor microenvironment to improve osteosarcoma outcomes

Targeting the tumor microenvironment to improve osteosarcoma outcomes

Meta analysis highlights prognostic role of circPVT1 in solid tumors

Meta analysis highlights prognostic role of circPVT1 in solid tumors

Unmasking Nrf2 as a key driver of treatment resistance in osteosarcoma

Unmasking Nrf2 as a key driver of treatment resistance in osteosarcoma

Researchers discover a major driver of osteosarcoma

Researchers discover a major driver of osteosarcoma

Researchers uncover new mutation mechanism driving cancer progression

Researchers uncover new mutation mechanism driving cancer progression

Study provides new insights into the genetic underpinnings of pediatric cancers

Study provides new insights into the genetic underpinnings of pediatric cancers

Pioneering research identifies three subtypes of osteosarcoma for better treatment

Pioneering research identifies three subtypes of osteosarcoma for better treatment

Researchers develop novel oxygen-independent therapy for cancer

Researchers develop novel oxygen-independent therapy for cancer

UCLA develops largest collection of patient-derived organoids for sarcoma research

UCLA develops largest collection of patient-derived organoids for sarcoma research

Bioactive glasses with gallium show promise for bone cancer treatment

Bioactive glasses with gallium show promise for bone cancer treatment

Review explores WNT5B and WNT10B roles in osteosarcoma

Review explores WNT5B and WNT10B roles in osteosarcoma

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.